Nanostics Inc., a precision health company specializing in diagnostic tests through its ClarityDX® platform, has partnered with OncoHelix, a leader in precision diagnostics. Together, they will offer ClarityDX Prostate® to healthcare providers and men in the Middle East.
ClarityDX Prostate, a cutting-edge diagnostic tool, combines biological data, clinical information, and AI-powered models to generate a risk score for aggressive prostate cancer. This marks a major step forward in prostate cancer screening, aiding men and their healthcare providers in making more informed decisions about biopsies following high PSA levels or abnormal DRE results.
OncoHelix, a leader in advanced molecular diagnostics, offers comprehensive testing services in the Middle East and North Africa (MENA) region through OncoHelix-coLAB, a state-of-the-art facility in Burjeel Medical City, Abu Dhabi. This lab, a joint venture between OncoHelix and Burjeel Holdings, now includes Nanostics’ ClarityDX Prostate test, enhancing diagnostic and treatment outcomes for men at risk of aggressive prostate cancer.
Dr. John Lewis, CEO of Nanostics, emphasized the global relevance of Alberta-developed technology, stating that the partnership with OncoHelix will help men in the Middle East benefit from early detection and better outcomes. Faisal Khan, CEO of OncoHelix, expressed excitement about the partnership, noting that the ClarityDX Prostate test will provide healthcare providers with valuable data-driven insights for early detection and targeted treatment in the region.
ClarityDX Prostate is available in the USA as CDX Prostate through Protean BioDiagnostics and in Canada through Nanostics’ CPSA-accredited lab in Alberta. In Quebec, testing services are available from CDL Laboratories.
About OncoHelix
OncoHelix, based in Calgary, is recognized as a leader in advanced molecular and immune diagnostics in Canada and internationally. The company offers a wide range of precision oncology tests and is expanding into wellness and reproductive health. OncoHelix partners with the Hematology Translational Lab (HTL) at the University of Calgary and operates the OncoHelix-coLAB in Abu Dhabi, providing cutting-edge diagnostic solutions in the UAE and broader MENA region.
